Cernostics: Here's what Cernostics' acquisition means for the longtime Pittsburgh company
The $30 million deal - which could include $50 million more depending on the progress of benchmarks - a growing field for the Texas-based biotech company.
Read full article »
Cernostics is a provider of tissue-based cancer diagnostics and prognostics test solutions.
Read more